IDEAYA Biosciences (IDYA) Net Cash Flow (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Net Cash Flow of $45.0 million for Q1 2026, up 124.19% sequentially from -$185.9 million in Q4 2025, and down 1.44% YoY from $45.6 million in Q1 2025.
IDEAYA Biosciences (IDYA) Net Cash Flow (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Net Cash Flow for 9 years, with the latest figure at $45.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 1.44% year-over-year to $45.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.0 million (up 29.05% YoY) and the FY2025 annual result came in at $28.7 million, up 139.48% from the prior year.
- Net Cash Flow grew to $45.0 million in Q1 2026 per IDYA's latest filing, from -$185.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $217.2 million in Q3 2024 and troughed at -$316.0 million in Q4 2024.
- A 5-year average of $3.9 million and a median of $5.2 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow surged 685.64% in 2023, then tumbled 6173.63% in 2024.
- Over 5 years, Net Cash Flow stood at -$33.3 million in 2022, then soared by 115.61% to $5.2 million in 2023, then sank by 6173.63% to -$316.0 million in 2024, then jumped by 41.18% to -$185.9 million in 2025, then jumped by 124.19% to $45.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $45.0 million, -$185.9 million, and $184.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 115.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.07 Mn |
| Jun 30, 2026 | 115.07 Mn |
| Mar 31, 2026 | 44.96 Mn |
| Mar 31, 2026 | 44.96 Mn |
| Dec 31, 2025 | -185.89 Mn |
| Dec 31, 2025 | -185.89 Mn |
| Sep 30, 2025 | 184.28 Mn |
| Sep 30, 2025 | 184.28 Mn |
| Jun 30, 2025 | -15.35 Mn |
| Jun 30, 2025 | -15.35 Mn |
| Mar 31, 2025 | 45.62 Mn |
| Mar 31, 2025 | 45.62 Mn |
| Dec 31, 2024 | -316.01 Mn |
| Dec 31, 2024 | -316.01 Mn |
| Sep 30, 2024 | 217.23 Mn |
| Sep 30, 2024 | 217.23 Mn |
| Jun 30, 2024 | 74.86 Mn |
| Jun 30, 2024 | 74.86 Mn |
| Mar 31, 2024 | -48.67 Mn |
| Mar 31, 2024 | -48.67 Mn |